OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments
Giandomenico Roviello, Martina Catalano, Raffaella Santi, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 13
Giandomenico Roviello, Martina Catalano, Raffaella Santi, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 13
Showing 13 citing articles:
2025 Canadian Urological Association Expert Report: Muscle-invasive bladder cancer
Girish S. Kulkarni, Peter C. Black, Srikala S. Sridhar, et al.
Canadian Urological Association Journal (2025) Vol. 19, Iss. 1, pp. E1-16
Open Access | Times Cited: 1
Girish S. Kulkarni, Peter C. Black, Srikala S. Sridhar, et al.
Canadian Urological Association Journal (2025) Vol. 19, Iss. 1, pp. E1-16
Open Access | Times Cited: 1
Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma
Chia-Hsien Shih, Yu‐Hua Lin, Hao‐Lun Luo, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 7
Chia-Hsien Shih, Yu‐Hua Lin, Hao‐Lun Luo, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 7
Disitamab vedotin vs. gemcitabine-cisplatin regimen with immunotherapy: a comparative analysis of efficacy and safety in muscle-invasive bladder cancer
C. Zhang, Yipeng Yu, Qi Zhou, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
C. Zhang, Yipeng Yu, Qi Zhou, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies
Kyung Hwan Kim, Hye Won Lee, Hong Koo Ha, et al.
Investigative and Clinical Urology (2023) Vol. 64, Iss. 3, pp. 202-202
Open Access | Times Cited: 7
Kyung Hwan Kim, Hye Won Lee, Hong Koo Ha, et al.
Investigative and Clinical Urology (2023) Vol. 64, Iss. 3, pp. 202-202
Open Access | Times Cited: 7
Review on the Increasing Role for PSMA-Based Radioligand Therapy in Prostate Cancer
Finn Edler von Eyben, Irene Virgolini, Richard P. Baum
(2024)
Open Access | Times Cited: 2
Finn Edler von Eyben, Irene Virgolini, Richard P. Baum
(2024)
Open Access | Times Cited: 2
Advancing bladder cancer management: development of a prognostic model and personalized therapy
Xiang Huang, Guotu Du, Ying Yang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Xiang Huang, Guotu Du, Ying Yang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
GABBR2 as a Downstream Effector of the Androgen Receptor Induces Cisplatin Resistance in Bladder Cancer
Mohammad Amin Elahi Najafi, Masato Yasui, Yuki Teramoto, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 13733-13733
Open Access | Times Cited: 6
Mohammad Amin Elahi Najafi, Masato Yasui, Yuki Teramoto, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 13733-13733
Open Access | Times Cited: 6
Pelvic lymphadenectomy: Evaluating nodal stage migration and will rogers effect in bladder cancer
Lohit Sodagum, Rachel Passarelli, John Pfail, et al.
Urologic Oncology Seminars and Original Investigations (2023) Vol. 42, Iss. 1, pp. 21.e9-21.e20
Closed Access | Times Cited: 5
Lohit Sodagum, Rachel Passarelli, John Pfail, et al.
Urologic Oncology Seminars and Original Investigations (2023) Vol. 42, Iss. 1, pp. 21.e9-21.e20
Closed Access | Times Cited: 5
Application of nanotechnology in bladder cancer diagnosis and therapeutic drug delivery
Hangzhuo Li, Jian Zhu, Guojun Weng, et al.
Journal of Materials Chemistry B (2023) Vol. 11, Iss. 35, pp. 8368-8386
Closed Access | Times Cited: 4
Hangzhuo Li, Jian Zhu, Guojun Weng, et al.
Journal of Materials Chemistry B (2023) Vol. 11, Iss. 35, pp. 8368-8386
Closed Access | Times Cited: 4
Review on the Increasing Role for PSMA-Based Radioligand Therapy in Prostate Cancer
Finn Edler von Eyben, Irene Virgolini, Richard P. Baum
Cancers (2024) Vol. 16, Iss. 14, pp. 2520-2520
Open Access | Times Cited: 1
Finn Edler von Eyben, Irene Virgolini, Richard P. Baum
Cancers (2024) Vol. 16, Iss. 14, pp. 2520-2520
Open Access | Times Cited: 1
Therapeutic Potential of Regorafenib in Cisplatin-Resistant Bladder Cancer with High Epithelial–Mesenchymal Transition and Stemness Properties
Feng‐Che Kuan, Jhy‐Ming Li, Yun‐Ching Huang, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 24, pp. 17610-17610
Open Access | Times Cited: 2
Feng‐Che Kuan, Jhy‐Ming Li, Yun‐Ching Huang, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 24, pp. 17610-17610
Open Access | Times Cited: 2
GULP1 as a Downstream Effector of the Estrogen Receptor-β Modulates Cisplatin Sensitivity in Bladder Cancer
Tomoyuki Tatenuma, Takuo Matsukawa, Takuro Goto, et al.
Cancer Genomics & Proteomics (2024) Vol. 21, Iss. 6, pp. 557-565
Open Access
Tomoyuki Tatenuma, Takuo Matsukawa, Takuro Goto, et al.
Cancer Genomics & Proteomics (2024) Vol. 21, Iss. 6, pp. 557-565
Open Access
Lokal fortgeschrittene Stadien und perioperative Systemtherapien des Blasenkarzinoms
Leubet Yirga, Thomas Hilser, Boris Hadaschik, et al.
TumorDiagnostik & Therapie (2024) Vol. 45, Iss. 02, pp. 90-94
Closed Access
Leubet Yirga, Thomas Hilser, Boris Hadaschik, et al.
TumorDiagnostik & Therapie (2024) Vol. 45, Iss. 02, pp. 90-94
Closed Access
